• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research

    3/12/24 10:20:00 AM ET
    $AGRX
    $GSK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRX alert in real time by email

    New York, United States, March 12, 2024 (GLOBE NEWSWIRE) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases (STDs), the transmission of sexually transmitted infections (STIs), family planning, and birth control. The use of contraceptive drugs and emergency contraceptives, especially among adolescents, and an increase in awareness of sexually transmitted infections (STIs) are the primary factors driving the expansion of the global contraceptive drug market. The growing acceptance of oral contraceptives as an effective method of birth control and their popularity have contributed to the rise in contraceptive demand, especially in developed regions. In addition, a rise in awareness of modern contraceptive drugs in developing nations has contributed significantly to expanding the global market. However, significant market restraints include associated risks, sociocultural influences of contraceptives, and side effects such as infertility resulting from contraception. Contraceptives are drugs used to prevent unintended pregnancies and sexually transmitted diseases (STDs).

    Download Free Sample Report PDF @ https://straitsresearch.com/report/contraceptive-drugs-market/request-sample

    Preventing Unwanted Pregnancies and Growing Government and non-governmental organization (NGO) initiatives Drives the Global Market

    According to Straits Research, "The global contraceptive drugs market size was valued at USD 14.32 billion in 2021. It is expected to reach USD 28.96 billion by 2030, growing at a CAGR of 7.3% during the forecast period (2022–2030)." Globally, the poor and low-income population is disproportionately represented in the overall rate of unintended pregnancies. Using traditional methods to prevent pregnancy is one of the leading contributors to this prevalence. In addition, several health issues, such as anemia, malaria, HIV, and other sexually transmitted infections, are significantly linked to the adverse outcomes of adolescent pregnancy.

    Consequently, contraceptive drugs contribute significantly to reducing the incidence of unintended pregnancies. In addition to government organizations, several non-profit organizations run campaigns and programs to increase education and awareness regarding the use of contraceptives. In addition, the market's growth is anticipated to be fueled by an increase in unintended pregnancies and the measures taken by individuals in many nations to prevent these unwanted pregnancies.

    Government agencies have implemented strict birth control measures due to population growth and STDs. Government and non-government organizations have launched family planning and birth control programs. They also provide information on various contraceptive methods, regardless of gender, marital status, or sexual activity. People are now well-informed about the appropriate use of contraceptives, especially emergency contraceptives.

    Rising Disposable Income and Unmet Contraceptive Needs in Developing Countries Creates Tremendous Opportunities

    The combination of an increase in the median household income and a greater emphasis on living a healthy lifestyle has contributed to increased life expectancy. Due to the increased awareness of various diseases such as AIDS and several STDs, there has been a rise in contraceptive drugs. In addition, it has been demonstrated that an increase in disposable income significantly affects the adoption of contraceptive drugs among working-age individuals in developing economies. In recent years, there has been a rise in spending on various contraceptive drugs and preventative measures due to greater awareness of modern contraceptive methods. One out of ten married or cohabiting women in the majority of the world has an unmet need for family planning. Consequently, this creates lucrative opportunities for market participants in developing nations to invest in contraceptive development programs and provide access to these contraceptive drugs for the entire population.

    Regional Analysis

    North America contraceptive drugs market share is estimated to grow at a CAGR of 7.0% during the forecast period. The rates of contraceptive use in this region have not changed significantly over the past few years, and it is anticipated that these rates will continue to fall over the next few years. Despite this, the region has the highest prevalence of the use of contraceptives at present. Pills, injectables, and patches are just some of the effective contraceptive options that are very popular in this part of the world. It is anticipated that after the United States, Europe will hold the second-leading position on the global market for contraceptive drugs.

    Key Highlights

    • Based on product, the global contraceptive drug market is divided into oral contraceptives, oral pills, topical contraceptives, and injectable contraceptives. The oral contraceptive pills segment is the highest contributor to the market, growing at a CAGR of 6.8% during the forecast period.
    • Based on the age group, the global contraceptive drug market is divided into 15-24 years, 25-34 years, 35-44 years, and 45 years. The 15-24 years segment is the highest contributor to the market, growing at a CAGR of 6.9% during the forecast period.
    • Based on the end-user, the global contraceptive drug market is divided into homecare, clinics, and hospitals. The home care segment is the highest contributor to the market, growing at a CAGR of 6.9% during the forecast period.
    • North America was the highest revenue contributor to the global contraceptive drugs market and is estimated to reach USD 10.17 billion by 2030, growing at a CAGR of 7.0% during the forecast period.

    Competitive Players

    The Top 10 players in the global contraceptive drugs market are Agile Therapeutics, Allergan Plc, Bayer AG, GlaxoSmithKline Plc, Johnson & Johnson, Piramal Healthcare, Pfizer Inc., Mylan N.V., Novartis AG, and Teva Pharmaceutical Industries Ltd. Other players operating in the market are Sanofi and HLL Lifecare Ltd.

    Market News

    • May 2022- GSK acquired clinical-stage biopharmaceutical company Affinivax, Inc. GSK plc (NYSE:GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts.
    • May 2022- NetVation DL Medicine Announced Research Collaboration with Pfizer Inc. NetVation DL Medicine ("DL Medicine"), a privately held biotechnology company based in Chengdu, China, and focused on the discovery and development of novel drug candidates, announced that it has entered into a two-year research collaboration with Pfizer Inc.
    • March 2022- Agile therapeutics partnered with award-winning director Maya Albanese on the first twirl commercial, targeting gen Z. Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company, announced the launch of its first consumer commercial intended to increase awareness of the Twirla weekly birth control patch.

    Global Contraceptive Drugs Market: Segmentation

    By Product

    • Oral Contraceptive Pills
    • Injectable Contraceptives
    • Topical Contraceptives

    By Age Group

    • 15–24 years
    • 25–34 years
    • 35–44 years
    • Above 44 years

    By End-User

    • Homecare
    • Hospitals
    • Clinics

    By Regions

    • North America
    • Europe
    • Asia-Pacific
    • LAMEA

    Get Detailed Market Segmentation @ https://straitsresearch.com/report/contraceptive-drugs-market/segmentation

    About Straits Research Pvt. Ltd.

    Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

    Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client's purchase. We overcome our clients' issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

    For more information on your target market, please contact us below:

    Phone: +1 646 905 0080 (U.S.)

    +91 8087085354 (India)

    +44 203 695 0070 (U.K.)

    Email: [email protected]

    Follow Us: LinkedIn | Facebook | Instagram | Twitter



    Primary Logo

    Get the next $AGRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGRX
    $GSK

    CompanyDatePrice TargetRatingAnalyst
    GSK plc
    $GSK
    4/15/2025$35.25Neutral
    Exane BNP Paribas
    GSK plc
    $GSK
    2/12/2025Equal-Weight
    Morgan Stanley
    GSK plc
    $GSK
    11/15/2024Buy → Hold
    Deutsche Bank
    GSK plc
    $GSK
    11/12/2024$53.00 → $39.50Buy → Hold
    Jefferies
    GSK plc
    $GSK
    10/31/2024Buy → Neutral
    Guggenheim
    GSK plc
    $GSK
    7/8/2024Buy → Neutral
    UBS
    GSK plc
    $GSK
    5/30/2024$47.00Neutral
    Goldman
    GSK plc
    $GSK
    3/4/2024Neutral → Buy
    Guggenheim
    More analyst ratings

    $AGRX
    $GSK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by GSK plc

      SC 13G/A - GSK plc (0001131399) (Subject)

      11/12/24 4:32:59 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/22/24 4:50:46 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Agile Therapeutics Inc.

      SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)

      7/9/24 2:20:54 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    SEC Filings

    See more
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/9/25 10:05:59 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 1:49:29 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by GSK plc

      6-K - GSK plc (0001131399) (Filer)

      5/8/25 11:26:51 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Administrative Officer Gilmore Geoffrey returned $30,789 worth of shares to the company (20,256 units at $1.52), closing all direct ownership in the company (SEC Form 4)

      4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)

      8/26/24 5:45:24 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Coiante Scott M returned $30,522 worth of shares to the company (20,080 units at $1.52), closing all direct ownership in the company (SEC Form 4)

      4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)

      8/26/24 5:42:38 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Supply Chain Officer Conway Robert G returned $20,564 worth of shares to the company (13,529 units at $1.52), closing all direct ownership in the company (SEC Form 4)

      4 - AGILE THERAPEUTICS INC (0001261249) (Issuer)

      8/26/24 5:41:41 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    Leadership Updates

    Live Leadership Updates

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

      TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab

      11/18/24 7:30:00 AM ET
      $GSK
      $MDCX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis

      Pretty Hurts, a new Lifetime Original Movie brought to you by GSK, informs Lifetime's mom audience about meningococcal disease, known as meningitis Partnership is part of GSK's Ask2BSure campaign, which encourages parents of teens and young adults ages 16-23 to start a conversation with their teen's doctor about meningitis and vaccination Hollywood moms of teens, Alyson Hannigan and Sarah Michelle Gellar, team up with GSK and Ask2BSure to help raise awareness GSK plc (LSE/NYSE:GSK) today announced its sponsorship of Pretty Hurts, a gripping new Lifetime Original Movie and the latest extension of GSK's Ask2BSure public health campaign. Premiering on June 28, 2025, at 8 p.m. ET/7 p.m.

      5/9/25 9:00:00 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

      --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). Alector and GSK are co-developing AL101, an investigational hum

      4/17/25 8:00:00 AM ET
      $ALEC
      $GSK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices

      Over 13 million adults aged 50-59 at increased risk in the US can potentially benefit from RSV immunization1 RSV causes an estimated 42,000 hospitalizations* each year in adults aged 50-64 years old in the US2 GSK plc (LSE/NYSE:GSK) is pleased that the Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the use of RSV vaccines including GSK's AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 50-59 who are at increased risk for severe RSV disease. This includes people with conditions like COPD, asthma, diabetes, heart disease and those in residential care3. This expands on ACIP's previous vote in June 2024 to recommend RSV vaccines fo

      4/16/25 5:36:00 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on GlaxoSmithKline with a new price target

      Exane BNP Paribas initiated coverage of GlaxoSmithKline with a rating of Neutral and set a new price target of $35.25

      4/15/25 12:40:46 PM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on GlaxoSmithKline

      Morgan Stanley initiated coverage of GlaxoSmithKline with a rating of Equal-Weight

      2/12/25 7:05:11 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GlaxoSmithKline downgraded by Deutsche Bank

      Deutsche Bank downgraded GlaxoSmithKline from Buy to Hold

      11/15/24 7:46:43 AM ET
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AGRX
    $GSK
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

      Highlights Second quarter revenue grew 15% year-over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22%), and Hereditary Cancer (19%).Second quarter GAAP earnings per share improved to $(0.41) from $(1.42) in the second quarter of 2023; adjusted earnings per share improved to $0.05 from $(0.08) in the second quarter of 2023.Increasing 2024 financial guidance with full year revenue moving to a range of $835 - $845 million, or an annual growth rate of between 11% and 12%, and increasing adjusted earnings per share (EPS) to a range of $0.08 - $0.12.1 _________________________1 The company does not forecast GAAP EPS because it cannot predict certain elements that are include

      8/6/24 4:05:00 PM ET
      $GSK
      $MYGN
      $PSNL
      $QGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Medical Specialities
    • GSK and CureVac to Restructure Collaboration into New Licensing Agreement

      GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinationsCureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replacedLONDON, UK, TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA

      7/3/24 2:40:00 AM ET
      $CVAC
      $GSK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

      First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope

      5/15/24 4:10:00 PM ET
      $AGRX
      Biotechnology: Pharmaceutical Preparations
      Health Care